John Radford

Scopus Author ID ResearcherID Scopus Author ID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 19

Top Topics

Hodgkin Lymphoma

Stem Cell Transplantation

Ejection Fraction

Top Venues

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Leukemia & lymphoma

This page only lists publications with an associated author ORCID identifier.

Publications

John Radford
Doxorubicin and Breast Cancer Risk: The Importance of Long-Term Follow-Up in Curable Cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 42 (16) (2024)
John Radford
Doxorubicin and Breast Cancer Risk: The Importance of Long-Term Follow-Up in Curable Cancers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2024)
Greg Hapgood, Monica Civallero, Yana Stepanishyna, Julie M Vose, María Elena Cabrera, Ranjana H Advani, Stefano A Pileri, Martina Manni, Steven M Horwitz, Francine M Foss, Felicitas Hitz, John Radford, Ivan Dlouhy, Carlos Sérgio Chiattone, Won-Seog Kim, Tetiana Skrypets, Arnon Nagler, Judith Trotman, Stefano Luminari, Massimo Federico
The SALENTO prognostic model for limited-stage peripheral T-cell lymphoma from the International T-Cell Project Network. Blood advances (2023)
Juan Pablo Alderuccio, Isildinha M Reis, Mehdi Hamadani, Muthiah Nachiappan, Salman Leslom, Brad S Kahl, Weiyun Z Ai, John Radford, Melham M Solh, Kirit M Ardeshna, Brian T Hess, Matthew A Lunning, Pier Luigi Luigi Zinzani, Anastasios Stathis, Carmello Carlo-Stella, Izidore S Lossos, Paolo F Caimi, Sunwoo Han, Fei Yang, Russ A Kuker, Craig H Moskowitz
PET/CT-biomarkers enable risk stratification of patients with relapsed/refractory diffuse large B-cell lymphoma enrolled in the LOTIS-2 clinical trial. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Stefano Luminari, Alexander Fossa, Judith Trotman, Daniel Molin, Francesco d'Amore, Gunilla Enblad, Leanne Berkahn, Sally F Barrington, John Radford, Massimo Federico, Amy A Kirkwood, Peter W M Johnson
Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Mehdi Hamadani, Alexander I Spira, Xiaolei Zhou, Laura Liao, Lei Chen, John Radford, Weiyun Z Ai, Melhem M Solh, Kirit M Ardeshna, Brian T Hess, Paolo F Caimi, Anastasios Stathis, Carmelo Carlo Stella, Juan Pablo Alderuccio, Brad S Kahl, Ying Wang, Yajuan Gu Qin, Zhiying Cindy Xu, Pier Luigi Luigi Zinzani
Clinical Outcomes of Older and Younger Patients Treated with Loncastuximab Tesirine in the LOTIS-2 Clinical Trial. Blood advances (2023)
Peter A Henriksen, Peter S Hall, Iain R J Macpherson, Shruti S Joshi, Trisha Singh, Morag Maclean, Stephanie Lewis, Aryelly Rodriguez, Alexander J Fletcher, Russell J Everett, Harriet Stavert, Angus Broom, Lois Eddie, Lorraine Primrose, Heather McVicars, Pamela McKay, Annabel Borley, Clare Rowntree, Simon R Lord, Graham P Collins, John Radford, Amy Guppy, Michelle Claire Williams, Alan Japp, John R Payne, David E Newby, Nicholas L Mills, Olga Oikonomidou, Ninian N Lang
Multicenter, Prospective, Randomized Controlled Trial of High-Sensitivity Cardiac Troponin I-Guided Combination Angiotensin Receptor Blockade and Beta-Blocker Therapy to Prevent Anthracycline Cardiotoxicity: The Cardiac CARE Trial. Circulation (2023)
Philippe Armand, Pier Luigi Luigi Zinzani, Jee Hun Lee, Nathalie A Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A Shipp, Alex F Herrera, Jianxin Lin, Eunhee Kim, Samhita Chakraborty, Patricia Marinello, Craig H Moskowitz
Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy in relapsed/refractory classical Hodgkin lymphoma. Blood (2023)
Paola Ghione, M Lia Palomba, Anik R Patel, Sabela Bobillo, Kevin Deighton, Caron A Jacobson, Myrna Nahas, Anthony James Hatswell, A Scott Jung, Steve Kanters, Julia Thornton Snider, Sattva S Neelapu, Maria Teresa Ribeiro, M Alan Brookhart, Herve Ghesquieres, John Radford, John G Gribben
Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma. Blood 140 (8) (2022)
Mahmoud Elsawy, Julio C Chavez, Irit Avivi, Jean-François Larouche, Luciano Wannesson, Kate Cwynarski, Keren Osman, Kelly Davison, Jakob D Rudzki, Saurabh Dahiya, Kathleen A Dorritie, Samantha M Jaglowski, John Radford, Judith Trotman, David Cunningham, Alejandro Martin Martin Garcia-Sancho, Dimitrios Tzachanis, Matthew L Ulrickson, Reem Karmali, Natasha Kekre, Catherine Thieblemont, Gunilla Enblad, Peter Dreger, Ram Malladi, Namita Joshi, Wei-Jhih Wang, Caitlyn T Solem, Julia Thornton Snider, Paul Cheng, Christina To, Marie José Kersten
Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. Blood 140 (21) (2022)
Juan Pablo Alderuccio, Weiyun Z Ai, John Radford, Melhem Solh, Kirit M Ardeshna, Matthew A Lunning, Brian T Hess, Pier L Zinzani, Anastasios Stathis, Carmelo Carlo-Stella, Mehdi Hamadani, Brad S Kahl, David Ungar, Turk Kilavuz, Eric Yu, Yajuan Qin, Paolo F Caimi
Loncastuximab tesirine in relapsed/refractory high-grade B-cell lymphoma: a subgroup analysis from the LOTIS-2 study. Blood advances 6 (16) (2022)
Martin Hutchings, John Radford, Stephen M Ansell, Árpád Illés, Anna Sureda, Joseph M Connors, Alice Sýkorová, Hirohiko Shibayama, Jeremy S Abramson, Neil S Chua, Jonathan W Friedberg, Jan Kořen, Ann Steward LaCasce, Lysiane Molina, Gerald Engley, Keenan Fenton, Hina Jolin, Rachael Liu, Ashish Gautam, Andrea Gallamini
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study. Hematological oncology 39 (2) (2021)
Alex F Herrera, Catherine Burton, John Radford, Fiona Miall, William Townsend, Armando Santoro, Pier Luigi Luigi Zinzani, David Lewis, Camilla Fowst, Satjit Brar, Bo Huang, Aron Thall, Graham P Collins
Avelumab in relapsed/refractory classical Hodgkin lymphoma: phase 1b results from the JAVELIN Hodgkins trial. Blood advances 5 (17) (2021)
Ranjana H Advani, Tetiana Skrypets, Monica Civallero, Michael A Spinner, Martina Manni, Won Seog Kim, Andrei R Shustov, Steven M Horwitz, Felicitas Hitz, Maria Elena Cabrera, Ivan Dlouhy, José Vassallo, Stefano A Pileri, Giorgio Ga Inghirami, Silvia Montoto, Umberto Vitolo, John Radford, Julie M Vose, Massimo Federico
Outcomes and prognostic factors in angioimmunoblastic T-cell lymphoma: final report from the international T-cell Project. Blood 138 (3) (2021)
David J Cutter, Johanna Ramroth, Patricia Diez, Andy Buckle, Georgios Ntentas, Bilyana Popova, Laura Clifton-Hadley, Peter J Hoskin, Sarah C Darby, John Radford, Timothy M Illidge
Predicted Risks of Cardiovascular Disease Following Chemotherapy and Radiotherapy in the UK NCRI RAPID Trial of Positron Emission Tomography-Directed Therapy for Early-Stage Hodgkin Lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (32) (2021)
Mehdi Hamadani, John Radford, Carmello Carlo-Stella, Paolo F Caimi, Erin G Reid, Owen A O'Connor, Jay M Feingold, Kirit M Ardeshna, William Townsend, Melhem Solh, Leonard T Heffner, David Ungar, Luqiang Wang, Joseph Boni, Karin Havenith, Yajuan Qin, Brad S Kahl
Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood 137 (19) (2021)
Adam Gibb, Sarah J Pirrie, Kim M Linton, Victoria Warbey, Kathryn Paterson, Andrew John Davies, Graham P Collins, Tobias Menne, Pamela McKay, Paul A Fields, Fiona M Miall, Eszter Nagy, Keith Wheatley, Rachel Reed, Ivona Baricevic-Jones, Sally F Barrington, John Radford
Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY). British journal of haematology 193 (1) (2020)
Pier Luigi Zinzani, Robert Chen, Philippe Armand, Nathalie A Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A Shipp, Jianxin Lin, Akash Nahar, Arun Balakumaran, Craig H Moskowitz
Pembrolizumab monotherapy in patients with primary refractory classical hodgkin lymphoma who relapsed after salvage autologous stem cell transplantation and/or brentuximab vedotin therapy: KEYNOTE-087 subgroup analysis. Leukemia & lymphoma 61 (4) (2020)
John Radford
Treatment of Hodgkin lymphoma in older patients. Blood 126 (26) (2016)